Summit Therapeutics (SMMT) Cash from Operations (2017 - 2026)

Summit Therapeutics (SMMT) has 10 years of Cash from Operations data on file, last reported at 141124000.0 in Q2 2026.

• Quarterly Cash from Operations fell 111.44% year-over-year to 141124000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 458433000.0 (down 121.59% YoY) and the FY2025 annual result came in at 322930000.0, down 127.25% from the prior year.
• Cash from Operations retreated to 141124000.0 in Q2 2026, from 122291000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 5191000.0 in Q4 2022 to a low of 141124000.0 in Q2 2026.
• A 5-year average of 47044055.56 and a median of 30215500.0 in 2024 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2022 — Cash from Operations surged 156.55% — and 2023, when it plunged 474.86%.
• Tracing SMMT's Cash from Operations over 5 years: stood at 5191000.0 in 2022, then sank by 474.86% to 19459000.0 in 2023, then tumbled by 150.13% to 48673000.0 in 2024, then tumbled by 109.43% to 101938000.0 in 2025, then tumbled by 38.44% to 141124000.0 in 2026.
• The last three Cash from Operations figures came in at 141124000.0 (Q2 2026), 122291000.0 (Q1 2026), and 101938000.0 (Q4 2025), per Business Quant data.